CORRECTION OF ESTROGEN DEFICIENCIES IN WOMEN WITH UROGENITAL DISORDERS


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Older women are more often prone to menopausal urogenital disorders caused by estrogen deficiency. In postmenopausal women, urogenital disorders do not generally belong to infectious diseases. The basis for their pathogenesis is the reduced production of female sex hormones. Local administration of estriol as ovestin vaginal cream and suppositories is recognized to be one of the safest treatments. With the treatment cycle completed, switching to maintenance therapy is indicated. Thus, therapy with the local ovestin formulations is a highly effective method for the treatment and prevention of lower urogenital tract diseases caused by age-related estrogen deficiency.

Толық мәтін

Рұқсат жабық

Авторлар туралы

Elena Sycheva

V.I. Kulakov Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: e_sycheva@oparina4.ru
gynecologist of the Polyclinic Department at Academician 117997, Russia, Moscow, Ac. Oparina str. 4

Inna Apolikhina

V.I. Kulakov Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia; I.M. Sechenov 1st Moscow State Medical University Ministry of Health of Russia

Email: apolikhina@inbox.ru
MD, Head of the gynecological department of rehabilitation treatment; Professor of the Department of Obstetrics, Gynecology, Perinatology and Reproductology of the Faculty of Postgraduate Professional Education of Physicians 117997, Russia, Moscow, Ac. Oparina str. 4

Әдебиет тізімі

  1. Вишневский А. Г., Андреева Е. М., Трейвиш А. И. Перспективы развития России: роль демографического фактора. М.: ИЭПП; 2003: 61.
  2. Кулаков В.И., Савельева Г.М., Манухин И.Б., ред. Гинекология. Национальное руководство. М.: ГЭОТАР-Медиа; 2009. 1088 с.
  3. Reigota R.B., Pedro A.O., de Souza Santos Machado V., Costa-Paiva L., Pinto-Neto A.M. Prevalence of urinary incontinence and its association with multimorbidity in women aged 50 years or older: A population-based study. Neurourol. Urodyn. 2014; Oct 30.
  4. Cooper J., Annappa M., Quigley A., Dracocardos D., Bondili A., Mallen C. Prevalence of female urinary incontinence and its impact on quality of life in a cluster population in the United Kingdom (UK): a community survey. Prim. Health Care Res. Dev. 2014; Oct 2: 1-6.
  5. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013; 20(9): 888-902.
  6. Балан В.Е. Вагинальная атрофия в климактерии. Эффективная фармакотерапия.2009; 3: 44-7.
  7. Kunin C.M., Evans C., Bartholomew D., Bates D.G. The antimicrobial defense mechanism of the female urethra: a reassessment. J.Urol. 2002; 168(2): 413-9.
  8. Spinillo A., Bernuzzi A.M., Cevini C., Gulminetti R., Luzi S., De Santolo A. The relationship of bacterial vaginosis, Candida and Trichomonas infection to symptomatic vaginitis in postmenopausal women attending a vaginitis clinic. Maturitas. 1997; 27(3): 253-60.
  9. RazR., ColodnerR., Rohana Y., BattinoS., Rottensterich E., WasserI.,Stamm W. Effectiveness of estriol-containing vaginal pessaries and nitrofurantion macrocrystal therapy in the prevention of recurrent urinary tract infection in postmenopausal women. Clin. Infect. Dis. 2003; 36(11): 1362-8.
  10. Пушкарь Д.Ю. Тазовые расстройства у женщин. М.: МЕДпресс- информ; 2006. 256с.
  11. Cavallini A., Dinaro E., Giocolano A., Caringella A.M., Ferreri R., Tutino V., Loverro G. Estrogen receptor (ER) and ER-related receptor expression in normal and atrophic human vagina. Maturitas. 2008; 59(3): 219-25.
  12. Балан В. Е., Ковалева Л.А. Новое в лечении пациенток с урогенитальной атрофией и рецидивирующими инфекциями мочевых путей. Эффективная фармакотерапия. 2010; 1: 20-4.
  13. Bachmann G.A., Notelovitz M., Kelly S.J., Thompson C. Long-term nonhormonal treatment of vaginal dryness. Clin. Pract. Sexuality. 1992; 8: 3-8.
  14. Liu H.T., Lin H, Kuo H.C. Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy. Neurourol. Urodyn. 2011; 30(8): 1525-9.
  15. Liu H.T., Kuo H.C. Urinary nerve growth factor levels are elevated in patients with overactive bladder and do not significantly increase with bladder distention. Neurourol. Urodyn. 2009; 28(1): 78-81.
  16. Yokoyama T., Kumon H., Nagai A. Correlation of urinary nerve growth factor level with pathogenesis of overactive bladder. Neurourol. Urodyn. 2008; 27(5): 417-20.
  17. Cardozo L, Lose G, Mc Clish D., Versi E. A systematic review of the effects of estrogens for symptoms suggestive of overactive bladder. Acta Obstet. Genecol. Scand. 2004; 83(10): 892-7
  18. Балан В.Е., Анкирская А.С., Есесидзе З.Т., Муравьева В.В. Патогенез атрофического цистоуретрита и различные виды недержания мочи у женщин в климактерии. Consilium medicum. 2001; 3(7): 326-31.
  19. Кулаков В.И., Сметник В.П. Руководство по климактерию. М.: МИА; 2001. 685с.
  20. Weisberg E., Ayton R., Darling G., Farrell E., Murkies A., O’Neill S. et al. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric. 2005; 8(1): 83-92.
  21. Балан В.Е., Сметник В.П. Урогенитальные расстройства в климактерии. М.; 1998.
  22. Балан В.Е. Принципы заместительной гормонотерапии урогенитальных расстройств. Consilium medicum. 2003; 5(7): 413-7.
  23. Аполихина И.А, Горбунова Е.А. Клинико-морфологические аспекты вульвовагинальной атрофии. Медицинский совет. 2014; 9: 110-7.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2015

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>